Overview
Background
Professor Fairlie is an NHMRC Research Investigator Fellow (Level 3) (2022-present), a Node Leader of the ARC Centre of Excellence for Innovations in Peptide Protein Science, one of four Centre Directors and former Head of the Division of Chemistry of Structural Biology at the Institute for Molecular Bioscience (since 2009), and an Affiliate Professor of the School of Chemistry and Molecular Biosciences. He was previously an NHMRC Senior Principal Research Fellow (2012-2021), a Node Leader at the ARC Centre of Excellence in Advanced Molecular Imaging (2014-2021), an ARC Federation Fellow (2006-2011), an ARC Professorial Fellow (2002-2006), and Scientific Director and Chief Scientific Officer of a startup company. He undertook postdoctoral studies at Stanford University and University of Toronto, postgraduate studies at Australian National University and University of New South Wales, and undergraduate studies at University of Adelaide.
His research group works across the disciplines of chemistry (synthesis, structure, reaction mechanisms), biochemistry (enzyme inhibitors, protein-protein interactions, GPCRs, transcription factors), immunology (innate immune cells in health and disease, mucosal T cells), and pharmacology (molecular pharmacology and human cell signalling, experimental pharmacology in rodent models of human diseases). He has published over 450 scientific journal articles in high impact chemistry journals (e.g. Chem Rev, J Am Chem Soc, Angew Chem Int Edit, Chem Sci, J Med Chem, Org Lett, J Org Chem) and biology journals (e.g. Nature, Science, Nature Immunology, Immunity, Science Immunology, Nature Communications, J Exp Med, J Clin Invest, Proc Natl Acad Sci, Diabetes, Cancer Res, Br J Pharmacol). He has been a Highly Cited Researcher (Clarivate Analytics), with over 37,000 citations and 104 publications with over 100 citations (Google Scholar), and has collaborated with many of the world’s largest pharmaceutical and biotechnology companies.
Availability
- Professor David Fairlie is:
- Available for supervision
- Media expert
Fields of research
Research interests
-
Chemistry and Human Therapeutics
The Fairlie group works at the interface of chemistry, biology and disease. We study CHEMISTRY, BIOCHEMISTRY, PHARMACOLOGY and IMMUNOLOGY to better understand the detailed processes of life, ageing, disease and death. Our chemists use state of the art methods to invent new compounds that regulate enzymes, protein-protein interactions, cellular receptors, RNA or DNA. Our biochemists, cell biologists, pharmacologists and immunologists study enzymes, proteins, cells and rodents to understand biological processes and effects of novel compounds in models of human diseases. We elucidate mechanisms of chemical reactions, biological processes, disease development and drug action. We aim to develop new treatments for human inflammatory and respiratory diseases, cancers, metabolic diseases (type 2 diabetes, obesity, cardiovascular), viral infections and neurodegenerative disorders (e.g. Alzheimer’s disease). We also execute basic research to understand fundamental principles and processes in chemistry (medicinal, organic, biological, computational, bioinorganic), biochemistry (proteins, enzymes), pharmacology (cells, rodents, human tissues) and immunology (neutrophils, macrophages, mast cells, dendritic cells, complement, T cells, rodents).
-
Medicinal and Organic Chemistry
We develop skills in chemical synthesis, structure elucidation and chemical mechanisms. We design new molecules with the aid of computers, develop new methods to synthesize them, determine their structures, elucidate reaction mechanisms, and use small molecules to probe biological processes and to elucidate structure-activity relationships. We use a wide range of solution and solid phase organic synthesis methodologies to create bioactive molecules (e.g. de novo designed drugs, natural product analogues, and peptidomimetics), reactive intermediates, highly functionalised molecular templates, structural constraints, and artificial receptors. We are engaged in chemical design and structural analysis using computers, determination of chemical structures by NMR spectroscopy and X-ray crystallography, spectroscopic investigations of chemical and biological reactions, enzyme kinetics, cell biology, and molecular pharmacology in vitro and in vivo.
-
Biochemistry and Protein-Protein Interactions
One strategic theme is the development of small molecules to mimic or inhibit bioactive protein surfaces recognized by other proteins. Protein-protein interactions drive most biological processes, yet the vast majority of these interactions occur over very short time scales (fractions of seconds). To better understand such fleeting interactions, we have been developing mimics of protein surfaces and working towards studying their longer-lived interactions with protein partners. We have identified conformations of protein surfaces that are common recognition elements for protease enzymes, for classes of G protein-coupled receptors that act as sensors on cell surfaces, or for transcriptional receptors that mediate DNA-protein responses in cells. We have described small molecules that structurally and functionally mimic components of bioactive protein surfaces (beta strands, beta-sheets, beta and gamma turns, alpha helices, helix bundles, multi-loop bundles). There are numerous potential uses for each of these classes of protein surface mimics - with many potential therapeutic applications. Through the ARC Centre of Excellence for Innovations in Peptide and Protein Science, we are studying post-translational modifications of proteins, elucidating structures and activities of naturally occurring peptides, and designing and developing peptidomimetics with interesting chemical or biological properties.
-
Immunology
We aim to better understand the molecular basis of the immune response and study aspects of innate and adaptive immunity. Our group works with human neutrophils, macrophages, dendritic cells, mast cells, complement and T cells, investigating their recruitment, differentiation, signalling and modulation in immunity, including the effects of novel drug leads on their functions. We are especially interested in complement proteins, GPCRs, T cell receptors, proteases, HDACs, chemokines and cytokines. Our novel compounds are used to validate targets on human cells and human proteins, then investigated in rodent models of human diseases and then towards preclinical and clinical studies, sometimes with pharma/biotech partners. Understanding how new experimental drugs can stimulate/enhance immune responses or suppress proinflammatory mediators can help in the design and development of effective new therapies to combat a diverse range of important human diseases. Through the ARC Centre of Excellence in Advanced Molecular Imaging, we linked up with physicists, structural biologists and immunologists in Melbourne and Sydney to study the molecular basis of T cell mediated immunity. Through collaborations with the IMB Centre for Inflammation and Disease Research in Brisbane, we study innate immunity.
-
Molecular and Experimental Pharmacology
Our research on diseases involves basic, strategic and applied research in biochemistry and pharmacology directed at: (1) understanding how the immune system resolves infection (by parasites, viruses, bacteria) and tissue injury; (2) how prolonged inflammatory responses can cause debilitating chronic inflammatory diseases, including onset of cancers, metabolic diseases (obesity, type 2 diabetes, atherosclerosis, cardiovascular diseases), chronic inflammatory pain, and neurodegenerative diseases (e.g. Alzheimer's disease); and (3) how our novel compounds can act on human proteins, human and rodent cells and tissues, and rat or mouse models of human diseases. See links for our publications in all of these disease areas and allied chemical, biochemical and pharmacological research. We conduct molecular pharmacology (studies of novel ligand interactions with cellular receptors, modulation of intracellular signalling pathways using experimental new drugs discovered in our labs, mechanisms of physiological responses and disease induction/progression) and experimental pharmacology (studies of drug-induced effects in rodent models of human diseases, interrogating molecular mechanisms in vivo, examining human tissues from the clinic). Our goal is to discover new drugs, mechanisms of drug action and to understand disease development and how to treat it.
Research impacts
Our researchers work at interfaces of chemistry and biology to better understand the molecular mechanisms of life, ageing, disease and death.
Our chemists study organic, medicinal and biological chemistry, especially using organic synthesis, computer-aided molecular design, nuclear magnetic resonance spectroscopy to create new chemical structures that interact with or mimic protein surfaces. We discover new chemical structures, reactions and mechanisms; enzyme inhibitors, agonists and antagonists of protein function; and molecules that mimic the structures and functions of bioactive protein surfaces.
Our biologists study mechanisms of protein and cell activation, signalling pathways, biological processes, disease development and drug action. We use novel experimental compounds discovered in our group as molecular tools to interrogate the functions of human proteins and cells, and apply some of them to the treatment of animal models of human diseases.
Our interdisciplinary expertise can be combined across multiple subdisciplines of chemistry and biology to gain insights into biochemical processes, human physiology, disease pathology, and we develop skills in biochemistry, pharmacology, virology, immunology, oncology or neurobiology. We work, in some cases with industry partners, to discover new basic research and apply some of our discoveries to develop experimental treatments for viral or parasitic infections, such as HIV, dengue fever and malaria; inflammatory diseases, such as arthritis, asthma, inflammatory bowel disease and rare immunological disorders; metabolic and cardiovascular disorders linked to obesity and type 2 diabetes; neurodegenerative diseases and cancers.
Works
Search Professor David Fairlie’s works on UQ eSpace
1992
Journal Article
Flavones are inhibitors of HIV-1 proteinase
Brinkworth R.I., Stoermer M.J. and Fairlie D.P. (1992). Flavones are inhibitors of HIV-1 proteinase. Biochemical and Biophysical Research Communications, 188 (2), 631-637. doi: 10.1016/0006-291X(92)91103-W
1992
Journal Article
Zinc monoglycerolate - a slow-release source of therapeutic zinc: solubilization by endogenous ligands
Fairlie D.P., Whitehouse M.W. and Taylor R.M. (1992). Zinc monoglycerolate - a slow-release source of therapeutic zinc: solubilization by endogenous ligands. Agents and Actions, 36 (1-2), 152-158. doi: 10.1007/BF01991243
1992
Conference Publication
Tautomerism in Amide Complexes
Fairlie, DP and Woon, TC (1992). Tautomerism in Amide Complexes. WASHINGTON: AMER CHEMICAL SOC.
1992
Journal Article
Amide complexes of (diethylenetriamine)platinum(II)
Woon T.C. and Fairlie D.P. (1992). Amide complexes of (diethylenetriamine)platinum(II). Inorganic Chemistry, 31 (20), 4069-4074. doi: 10.1021/ic00046a016
1992
Conference Publication
Design and synthesis of new cavitands which are stereochemically rigid, hydrophobic and internally functionalised
Stoermer, M.J., Wickramasinghe, W., Weerasuria, K.D.V., Fairlie, D., Butler, D. and Warrener, R. (1992). Design and synthesis of new cavitands which are stereochemically rigid, hydrophobic and internally functionalised. Royal Australian Chemical Institute National Conference 1992, Monash University, Melbourne, Australia, 28 Sept - 2 October 1992.
1992
Journal Article
Inhibition of HIV-1 proteinase by metal ions
Woon T.C., Brinkworth R.I. and Fairlie D.P. (1992). Inhibition of HIV-1 proteinase by metal ions. International Journal of Biochemistry, 24 (6), 911-914. doi: 10.1016/0020-711X(92)90096-J
1991
Journal Article
Transdermal delivery of inorganic complexes as metal drugs or nutritional supplements
Fairlie, D. P. and Whitehouse, M. W. (1991). Transdermal delivery of inorganic complexes as metal drugs or nutritional supplements. Drug Design and Discovery, 8 (2), 83-102.
1991
Journal Article
Inhibition of HIV-1 proteinase by non-peptide carboxylates
Brinkworth, Ross I., Woon, Tai Chin and Fairlie, David P. (1991). Inhibition of HIV-1 proteinase by non-peptide carboxylates. Biochemical and Biophysical Research Communications, 176 (1), 241-246. doi: 10.1016/0006-291X(91)90915-T
1991
Journal Article
Factors Influencing the Nitrogen Vs Oxygen Bonding Mode of Amides Bound to Pentaamminecobalt(Iii) and the Kinetics and Mechanism of Rearrangement
Fairlie, David P., Angus, Patricia M., Fenn, M. David and Jackson, W. Gregory (1991). Factors Influencing the Nitrogen Vs Oxygen Bonding Mode of Amides Bound to Pentaamminecobalt(Iii) and the Kinetics and Mechanism of Rearrangement. Inorganic Chemistry, 30 (7), 1564-1569. doi: 10.1021/ic00007a026
1991
Conference Publication
Synthesis of cavitands as catalytic environments
Stoermer, Martin J. and Fairlie, David P. (1991). Synthesis of cavitands as catalytic environments. 12th National Conference of the Royal Australian Chemical Institute, Division of Organic Chemistry, University of Queensland, Australia, 1991.
1990
Journal Article
A general synthetic route to pentaamminecobalt(III) complexes of N-bonded amides, ureas, carbamates, sulfinamides, sulfonamides and sulfamate
Fairlie D.P. and Jackson W.G. (1990). A general synthetic route to pentaamminecobalt(III) complexes of N-bonded amides, ureas, carbamates, sulfinamides, sulfonamides and sulfamate. Inorganica Chimica Acta, 175 (2), 203-207. doi: 10.1016/S0020-1693(00)84828-8
1990
Journal Article
CORRECTION
FAIRLIE, DP (1990). CORRECTION. Inorganic Chemistry, 29 (18), 3630-3630. doi: 10.1021/ic00343a068
1990
Journal Article
Linkage Isomeric Pentaamminecobalt(Iii) Complexes of Methanesulfinamide
Fairlie, DP, Jackson, WG and Thompson, KH (1990). Linkage Isomeric Pentaamminecobalt(Iii) Complexes of Methanesulfinamide. Inorganic Chemistry, 29 (17), 3145-3150. doi: 10.1021/ic00342a018
1990
Journal Article
Nitrogen-Bonded and Oxygen-Bonded Urethane - Hydrolysis and Linkage Isomerization of [(Nh3)5Conh2Co2C2H5]3+ and [(Nh3)5Cooc(Nh2)Och2Ch3]3+
Fairlie, DP and Jackson, WG (1990). Nitrogen-Bonded and Oxygen-Bonded Urethane - Hydrolysis and Linkage Isomerization of [(Nh3)5Conh2Co2C2H5]3+ and [(Nh3)5Cooc(Nh2)Och2Ch3]3+. Inorganic Chemistry, 29 (17), 3139-3145. doi: 10.1021/ic00342a017
1990
Journal Article
Homogeneous Catalysis - Catalytic Intramolecular Conversion of 1,4-Dialdehydes to Gamma-Lactones
Bergens, SH, Fairlie, DP and Bosnich, B (1990). Homogeneous Catalysis - Catalytic Intramolecular Conversion of 1,4-Dialdehydes to Gamma-Lactones. Organometallics, 9 (3), 566-571. doi: 10.1021/om00117a006
1990
Journal Article
Linkage Isomerization of (Formamide-N)Pentaamminecobalt(Iii) and (Acetamide-N)Pentaamminecobalt(Iii) Ions in Water, Dimethyl-Sulfoxide, and Sulfolane
Angel, Robert L., Fairlie, David P. and Jackson, W. Gregory (1990). Linkage Isomerization of (Formamide-N)Pentaamminecobalt(Iii) and (Acetamide-N)Pentaamminecobalt(Iii) Ions in Water, Dimethyl-Sulfoxide, and Sulfolane. Inorganic Chemistry, 29 (1), 20-28. doi: 10.1021/ic00326a006
1990
Journal Article
Amination of Coordinated Nitriles - Synthesis of Metal-Complexes of Amidines and Guanidines
Fairlie, DP and Jackson, WG (1990). Amination of Coordinated Nitriles - Synthesis of Metal-Complexes of Amidines and Guanidines. Inorganic Chemistry, 29 (1), 140-143. doi: 10.1021/ic00326a030
1989
Journal Article
Cobalt-Induced Facile Degradation of Phenylurea to Ammonia, Carbon-Dioxide, and Anilinium Ion and Other Reactions of Linkage Isomeric Cobalt(Iii) Complexes of Phenylurea
Fairlie, David P., Jackson, W. Gregory and McLaughlin, George M. (1989). Cobalt-Induced Facile Degradation of Phenylurea to Ammonia, Carbon-Dioxide, and Anilinium Ion and Other Reactions of Linkage Isomeric Cobalt(Iii) Complexes of Phenylurea. Inorganic Chemistry, 28 (10), 1983-1989. doi: 10.1021/ic00309a043
1988
Journal Article
Reversible linkage isomerization of pentaamminecobalt(III) complexes of urea and its N-methyl derivatives
Fairlie D.P. and Jackson W.G. (1988). Reversible linkage isomerization of pentaamminecobalt(III) complexes of urea and its N-methyl derivatives. Inorganica Chimica Acta, 150 (1), 81-100. doi: 10.1016/S0020-1693(00)87628-8
1988
Journal Article
Homogeneous Catalysis - Conversion of 4-Pentenals to Cyclopentanones by Efficient Rhodium-Catalyzed Hydroacylation
Fairlie, David P. and Bosnich, B. (1988). Homogeneous Catalysis - Conversion of 4-Pentenals to Cyclopentanones by Efficient Rhodium-Catalyzed Hydroacylation. Organometallics, 7 (4), 936-945. doi: 10.1021/om00094a025
Funding
Current funding
Past funding
Supervision
Availability
- Professor David Fairlie is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Available projects
-
Targeting strategies for drug design
Selective binding of small molecules with proteins underpins most drug discovery. However, while a compound can be devised to interact with a single protein, this cannot drive the molecule into a specific location where functional modulation of the target protein only at that location is desired for therapy. Instead, designed compounds usually bind to the protein wherever it is expressed in the body and this can be deterimental to normal healthy physiology. This project will investigate a number of promising new approaches to directing protein-binding compounds to specific compartments of cells and organisms. It will require a combination of organic synthesis, medicinal chemistry, molecular modelling and chemical biology. The new approaches will be tested and optimised with the goal of inhibiting or activating desired proteins in specific compartments in order to modulate disease-causing protein functions without altering normal healthy physiology. Achieving these aims will require enthusiasm, a high degree of self-motivation, lateral thinking, strong chemical knowledge and hands-on skills in organic synthesis (solution and solid phase), NMR characterisation (including 2D NMR structure analysis), HPLC purification, mass spectrometry, and computer modelling. Some knowledge of enzyme assays and cell biology would be an advantage. The long term goal is to design new compounds and profile them for selective effects on target genes/proteins/cells/rodent models of inflammatory diseases and cancer. Outcomes will include new knowledge of protein function in disease; greater understanding of medicinal and organic chemistry in drug design, drug targeting, mechanisms and effectiveness of drug action; patentable methods and bioactive compounds; and new experimental leads to new medicines for development towards the clinic.
Supervision history
Current supervision
-
Doctor Philosophy
Novel chemical approaches to drugs that selectively target immune cells
Principal Advisor
Other advisors: Dr Jeffrey Mak
-
Doctor Philosophy
Developing a new type of drug for inflammatory disease
Principal Advisor
Other advisors: Dr Junxian Lim
-
Doctor Philosophy
Discovering novel anticancer drugs
Principal Advisor
Other advisors: Dr Jeffrey Mak, Dr Tim Hill
-
Doctor Philosophy
Novel activators and inhibitors of innate immune cells
Principal Advisor
Other advisors: Dr Jeffrey Mak
-
Doctor Philosophy
Peptide modulators for drug discovery
Principal Advisor
Other advisors: Dr Junxian Lim
-
Doctor Philosophy
New strategies in heterocyclic chemistry for drug discovery
Principal Advisor
Other advisors: Dr Jeffrey Mak
-
Doctor Philosophy
Therapeutic strategies to inhibit oncogenic transcription factors
Principal Advisor
Other advisors: Dr Junxian Lim
-
Doctor Philosophy
Design and synthesis of novel Major histocompatibility complex class I-Related protein ligands
Associate Advisor
Other advisors: Dr Jeffrey Mak
-
Doctor Philosophy
Combating bacterial infections through reprogramming of innate immunity
Associate Advisor
Other advisors: Dr Divya Ramnath, Professor Matt Sweet
-
Doctor Philosophy
Modulation of innate immune proteins in cancers
Associate Advisor
Other advisors: Dr Junxian Lim
Completed supervision
-
-
2021
Doctor Philosophy
Novel mechanistic insights into oxytocin receptor signalling in breast cancer
Principal Advisor
Other advisors: Associate Professor Markus Muttenthaler
-
2021
Doctor Philosophy
Targeting the oxytocin receptor for breast cancer imaging
Principal Advisor
Other advisors: Associate Professor Markus Muttenthaler
-
-
-
2020
Master Philosophy
Structure-function relationships of a ribityl uracil T-cell antigen
Principal Advisor
Other advisors: Dr Jeffrey Mak
-
2020
Doctor Philosophy
Protease-Activated Receptor 2 Connects Metabolism to Inflammation in Human Epithelial Cells
Principal Advisor
-
2020
Doctor Philosophy
Detecting Oxytocin: Mass spectrometry and PET-tracer development
Principal Advisor
Other advisors: Associate Professor Markus Muttenthaler
-
2020
Doctor Philosophy
Synthetic and Structural Studies of Small Cyclic Peptides
Principal Advisor
Other advisors: Dr Huy Hoang
-
2020
Doctor Philosophy
Profiling novel experimental drug candidates for inflammatory diseases
Principal Advisor
-
-
2020
Doctor Philosophy
GLP-1 Receptor Signaling By Novel GLP-1 Analogues
Principal Advisor
Other advisors: Dr Junxian Lim
-
2018
Doctor Philosophy
Modulating Protease-Activated Receptor 2
Principal Advisor
Other advisors: Dr Jacky Suen, Dr Junxian Lim
-
2017
Doctor Philosophy
Heterocyclic agonists and antagonists for the C3a receptor
Principal Advisor
-
-
2017
Doctor Philosophy
Computer Modeling of Protein-Ligand Interactions at Cell Surfaces
Principal Advisor
-
2016
Doctor Philosophy
Towards Cell Permeable Modulators of Protein-Protein Interactions
Principal Advisor
Other advisors: Dr Tim Hill
-
2016
Doctor Philosophy
Characterising Novel and Potent Modulators of Complement Receptor C3aR
Principal Advisor
-
2016
Doctor Philosophy
Structural Features in Orally Bioavailable Cyclic Peptides
Principal Advisor
Other advisors: Dr Tim Hill
-
-
2015
Doctor Philosophy
Towards inhibitors of hydrolytic enzymes involved in inflammation
Principal Advisor
-
2014
Doctor Philosophy
Properties of C5a Receptor on Human Macrophages
Principal Advisor
Other advisors: Dr Jacky Suen
-
-
2014
Doctor Philosophy
Novel Agonists & Antagonists for Protease-Activated Receptor 2 and C3a Receptor
Principal Advisor
-
2013
Doctor Philosophy
Links between inflammation and obesity
Principal Advisor
-
-
-
2012
Master Philosophy
Short Helix-Constrained Peptides As RSV Fusion Inhibitors And Vaccine Candidates
Principal Advisor
Other advisors: Professor Paul Young
-
2010
Doctor Philosophy
Alpha Helices Mimetics
Principal Advisor
-
2010
Doctor Philosophy
Structural Studies of Cyclic Peptides
Principal Advisor
Other advisors: Dr Huy Hoang
-
2010
Doctor Philosophy
Regulation of inflammatory proteins
Principal Advisor
Other advisors: Professor Matt Sweet
-
-
2009
Doctor Philosophy
Constraining short B cell epitopes as alpha helices
Principal Advisor
Other advisors: Professor Paul Young
-
-
2008
Master Philosophy
Design and Synthesis of HDAC inhibitors derived from a-aminosuberic acid
Principal Advisor
-
2008
Doctor Philosophy
Agonists and Antagonists of Protease Activated Receptor-2 (PAR 2)
Principal Advisor
-
-
-
2006
Doctor Philosophy
THE DESIGN, SYNTHESES AND STRUCTURES OF SMALL ALPHA-HELICAL PEPTIMOMIMETICS
Principal Advisor
-
2005
Doctor Philosophy
MOLECULAR CHARACTERISTICS OF AGONISTS AND ANTAGONISTS OF TWO G-PROTEIN COUPLED RECEPTORS
Principal Advisor
-
2002
Doctor Philosophy
MACROCYCLIC PSEUDOPEPTIDES AS MIMICS OF BIOACTIVE PROTEIN SURFACES
Principal Advisor
-
2002
Doctor Philosophy
NEW PROTEASE INHIBITORS AS PROBES OF BIOLOGICAL PROCESSES
Principal Advisor
-
2017
Doctor Philosophy
Investigations of the effects of scanning focused ultrasound in mouse models of Alzheimer's disease.
Associate Advisor
Other advisors: Professor Jürgen Götz
-
2015
Doctor Philosophy
Characterisation of Human Macrophage Functions in Innate Immunity
Associate Advisor
Other advisors: Professor Matt Sweet, Professor Kate Schroder
-
2014
Doctor Philosophy
Design, Synthesis and Evaluation of Peptides and Peptidomimetics Inhibiting the Bacterial DsbA-DsbB Interaction
Associate Advisor
-
2013
Doctor Philosophy
Stalking the West Nile Virus NS2B/NS3 protease as a target for infection control and as a key player in virus factories
Associate Advisor
Other advisors: Professor Alexander Khromykh, Professor Paul Young
-
-
2007
Doctor Philosophy
EFFECTS OF METAL BINDING ON PEPTIDE CONFORMATION
Associate Advisor
-
2007
Doctor Philosophy
STRUCTURE-FUNCTION RELATIONSHIPS OF THE WEST NILE VIRUS PROTEASE NS3 AND ITS COFACTOR NS2B
Associate Advisor
Other advisors: Professor Paul Young
-
2004
Doctor Philosophy
THE CHEMISTRY AND PHARMACOLOGY OF C3a AND C3a ANALOGUES
Associate Advisor
-
2003
Doctor Philosophy
INVESTIGATIONS OF ENCAPSULATING LIGAND SYSTEMS AND THEIR METAL COMPLEXES
Associate Advisor
-
2003
Doctor Philosophy
REACTIONS OF PLATINUM (II) COMPLEXES WITH SMALL PEPTIDES
Associate Advisor
Media
Enquiries
Contact Professor David Fairlie directly for media enquiries about:
- Alzheimer's disease
- biochemistry
- biological chemistry
- cancers
- cardiovascular disease
- dementia
- drug design
- drug discovery
- enzymes
- experimental pharmacology
- immunology
- infectious diseases
- inflammatory diseases
- innate immunity
- malaria
- Medicinal Chemistry
- metabolic disease
- metabolism
- metastasis
- molecular pharmacology
- neurodegenerative disease
- obesity
- organic chemistry
- pathogenesis
- peptides
- pharmaceuticals
- proteins
- respiratory disease
- signal transduction
- structural biology
- structural chemistry
- tropical diseases
- type 2 diabetes
- viral infections
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: